宫颈癌根治性放化疗中调强放疗使用趋势:2004-2019
该研究基于美国国家癌症数据库分析2004至2019年间接受根治性放化疗的IB2-IVA期宫颈癌患者,发现调强放疗使用率从2004年的31%升至2019年的75%(P<.01),且III期病变、淋巴结受累、西部或南部治疗及距治疗机构超过50英里的患者更可能接受IMRT,而黑种人及社区医院治疗者接受IMRT的可能性较低。
要点
- 宫颈癌根治性放化疗中IMRT使用率15年间从31%增至75%。
- III期病变和淋巴结受累与IMRT使用增加相关。
- 黑种人及社区医院治疗者接受IMRT的可能性较低。
核心结论
- 宫颈癌根治性放化疗中IMRT使用率在2004至2019年间显著增加,尤其在高分期或淋巴结受累患者中。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列研究,纳入2004至2019年诊断为IB2-IVA期并接受根治性放化疗的宫颈癌患者共16974例。
主要发现
- 5388例(32%)接受3DCRT,11586例(68%)接受IMRT。
- IMRT使用率从2004年的31%上升至2019年的75%(P<.01)。
- 与I期相比,III期病变与IMRT使用增加相关(OR=1.3,CI 1.0-1.5)。
- 淋巴结受累与IMRT使用增加相关(OR=1.4,CI 1.2-1.6)。
- 与东北部相比,西部(OR=1.5,CI 1.2-1.8)和南部(OR=1.3,CI 1.1-1.5)治疗与IMRT使用增加相关;距治疗机构超过50英里亦相关(OR=1.2,CI 1.0-1.5)。
临床怎么用
- 研究提示IMRT在宫颈癌根治性放化疗中已成为主流技术,临床决策时可结合分期、淋巴结状态及机构条件综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to identify temporal trends in intensity modulated radiation therapy (IMRT) use for patients with cervical cancer who received definitive chemoradiation. METHODS AND MATERIALS: Patients diagnosed with stage IB2-IVA cervical cancer between 2004 and 2019 and treated with definitive chemoradiation were identified in the National Cancer Database. The primary outcome of interest was the use of IMRT versus 3-dimensional conformal radiation therapy (3DCRT) over time. Wilcoxon rank-sum tests, chi-square tests, and multivariable logistic regression were used to identify factors associated with the receipt of IMRT. RESULTS: Overall, 16,974 patients were included: 5388 (32%) received 3DCRT, and 11,586 (68%) received IMRT. IMRT use increased from 31% in 2004 to 75% in 2019 (P < .01). Clinical factors associated with increased IMRT use were stage III disease compared with stage I (odds ratio [OR], 1.3; CI, 1.0-1.5) and lymph node involvement (OR, 1.4; CI, 1.2-1.6). The demographic factors associated with increased IMRT receipt were treatment in the western US (OR, 1.5; CI, 1.2-1.8) and in the southern US (OR, 1.3; CI, 1.1-1.5) compared with the northeastern US, and living more than 50 miles from the treatment facility (OR, 1.2; CI, 1.0-1.5). Compared with White patients, Black patients (OR, 0.8; CI, 0.6-0.9) and patients receiving care at community hospitals compared with academic medical centers (OR, 0.7; CI, 0.6-0.7) were less likely to receive IMRT. CONCLUSIONS: IMRT utilization for cervical cancer has increased over the last 15 years, especially for patients with advanced-stage disease or lymph node involvement. Understanding shifts in policy, demographic trends, and practice patterns may provide additional insight into the adoption of advanced technologies.
引用
- Lee SS, Weil CR, Boyd L, et al. Trends in Intensity Modulated Radiation Therapy Utilization for Definitive Treatment of Intact Cervical Cancer, 2004-2019. Adv Radiat Oncol. 2026. PMID: 42183318. doi:10.1016/j.adro.2026.102043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。